Care journeys of breast-cancer patients illuminated by AI

Allowing natural language processing to pore over disparate data stored in electronic health records, researchers in Canada have shown the AI-based technology can reveal real-world experiences and outcomes of patients with stage III breast cancer.

Mark Levine, MD, of McMaster University and colleagues had their work published online Aug. 1 in JCO Clinical Cancer Informatics.

After drawing and anonymizing data from 50 relevant patients in their health system’s EHR, the team developed specialized NLP annotators to mine unstructured clinical text and render it in a structured format.

To validate their approach, they applied the annotators to 19 more patients.

Their tool successfully extracted information on tumor stage, patient age, initial treatment and other factors that made it possible to build timelines showing key steps along patients’ care journeys.

Further, comparing the tool’s results with the gold standard—clinicians’ notes in medical charts—they found that, for 171 data elements, NLP and the chart agreed 76% of the time.

Moreover, with “additional manipulation using simple logic,” the disagreement was reduced to only six elements, the authors report.

“It is possible to extract, read and combine data from the EHR to view the patient journey,” Levine et al. concluded.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.